Sinovac (SVA) CFO Wang Nan discloses 355,000 common shares in Form 3

Rhea-AI Filing Summary

SINOVAC BIOTECH LTD Chief Financial Officer Wang Nan filed an initial ownership report showing holdings of 355,000 common shares. This Form 3 establishes Wang Nan’s existing direct ownership position in the company’s common equity and serves as a baseline for any future insider transactions.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

WANG NAN

(Last) (First) (Middle)

NO. 39, SHANGDI WEST ROAD

HAIDIAN DISTRICT

(Street)

BEIJING 100085

(City) (State) (Zip)

CHINA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
SINOVAC BIOTECH LTD [ SVA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common shares, par value $0.001 per share	355,000	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Jia Zhao, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Sinovac (SVA) Form 3 filed by Wang Nan report?

The Form 3 shows that Chief Financial Officer Wang Nan directly holds 355,000 common shares of Sinovac Biotech Ltd. This establishes a baseline ownership position for future insider transaction reporting.

Is Sinovac (SVA) CFO Wang Nan buying or selling shares in this Form 3?

This Form 3 does not report any share purchases or sales. It simply discloses that Wang Nan directly holds 355,000 common shares, as required when becoming a reporting insider.

How many Sinovac (SVA) shares does CFO Wang Nan directly own?

CFO Wang Nan directly owns 355,000 common shares of Sinovac Biotech Ltd. This amount is reported as the total number of shares beneficially owned following the reported holdings entry.

What is the significance of this Sinovac (SVA) Form 3 for investors?

The filing discloses the CFO’s initial ownership of 355,000 common shares. It does not indicate any transaction, but it provides transparency into management’s existing equity stake in the company.

Does the Sinovac (SVA) Form 3 show any derivative or option positions for Wang Nan?

The disclosed data show no derivative positions for Wang Nan. The filing only reports direct ownership of 355,000 common shares, with no options, warrants, or other derivative securities listed.